Roche Holding AG
SIX:ROG
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| CH |
|
Roche Holding AG
SIX:ROG
|
207B CHF |
27%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
681.8B USD |
78%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
366.7B USD |
30%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
88%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
181.7B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161B GBP |
20%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
191.6B USD |
39%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
70%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
131.8B USD |
9%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.1B EUR |
17%
|
Roche Holding AG
Glance View
Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on Roche Holding AG's most recent financial statements, the company has ROE of 27.1%.
You don't have any saved screeners yet